GELS
GELS
NASDAQ · Pharmaceuticals

Gelteq Ltd

$0.58
+0.02 (+3.42%)
Financial Highlights (FY 2026)
Revenue
197.3K
Net Income
-7,891,962
Gross Margin
30.3%
Profit Margin
-4,011.7%
Rev Growth
+3.9%
D/E Ratio
0.27
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 30.3% 30.3% 30.0% 30.0%
Operating Margin -3,015.9% -2,714.4% 23.0% 18.9%
Profit Margin -4,011.7% -3,811.2% 17.2% 17.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 197.3K 189.8K 1.91M 1.66M
Gross Profit 59.9K 57.6K 574.2K 499.6K
Operating Income -5,949,574 -5,152,137 441.1K 315.2K
Net Income -7,891,962 -6,834,182 328.9K 295.4K
Gross Margin 30.3% 30.3% 30.0% 30.0%
Operating Margin -3,015.9% -2,714.4% 23.0% 18.9%
Profit Margin -4,011.7% -3,811.2% 17.2% 17.7%
Rev Growth +3.9% +3.9% -9.8% +4.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 663.2K 663.2K 1.31M 1.18M
Total Equity 2.49M 2.49M 6.78M 6.33M
D/E Ratio 0.27 0.27 0.19 0.19
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,481,190 -4,096,151 495.2K 517.1K
Free Cash Flow 411.8K 446.0K